Spots Global Cancer Trial Database for Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer

Official Title: A Randomized Controlled Phase II Study on Intra-arterial Versus Intravenous Chemotherapy Infusion With Gemcitabine and Oxaliplatin for Locally Advanced Pancreatic Cancer

Study ID: NCT02635971

Conditions

Carcinoma, Pancreatic

Interventions

Transcatheter arterial infusion

Intravenous chemotherapy

Gemcitabine

Oxaliplatin

Study Description

Brief Summary: This study aims to explore the efficacy and safety of intra- arterial infusion of gemcitabine and oxaliplatin in locally advanced pancreatic cancer. This protocol is overseen by the Fudan University Institutional Review Board which has Federal Wide Assurance through the U.S. Department of Health \& Human Services (Approved: April 25, 2002).

Detailed Description: Primary Outcome Measures: To compare the overall survival (OS) in patients with locally advanced pancreatic cancer treated with transcatheter arterial infusion (TAI) of chemotherapeutics or systemic delivered chemotherapy. Secondary Outcome Measures: To compare the progression free survival (PFS), objective response rate (ORR), quality of life (QoL), and adverse effects of treating locally advanced pancreatic cancer patients with TAI or systemic chemotherapy. Exploratory Outcome Measures: To evaluate the correlation between prognosis and expression of serum microRNAs of the patients.